CAR T cells: Continuation in a revolution of immunotherapy

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · see citing works

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works

Graft-versus-leukemia reactions after bone marrow transplantation

Horowitz, M., Rp, G., Pm, S., Goldman, J. M., Kersey, J., Kolb, H., Rimm, A., Ringdén, O. T. H., Rozmán, C., & SPECK, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,769 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,484 · see citing works

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · see citing works

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,203 · see citing works

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system

Zinkernagel, R. M., & Doherty, P. C. (1974) · Nature · doi:10.1038/248701a0 · Cited by 2,102 · see citing works

Cancer Immunotherapy

Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · see citing works

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

Rosenberg, S. A., Spiess, P. J., & Lafrenière, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,888 · see citing works

Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus

Mann, R., Mulligan, R. C., & Baltimore, D. (1983) · Cell · doi:10.1016/0092-8674(83)90344-6 · Cited by 1,855 · see citing works

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · see citing works

Bone-Marrow Transplantation

Thomas, E. D., Storb, R., Ra, C., et al. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504172921605 · Cited by 1,716 · see citing works

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,714 · see citing works

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668 · see citing works

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Schuster, S., Svoboda, J., Chong, E., Nasta, S., Mato, A., Anak, Ö., Brogdon, J., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,599 · see citing works

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

Kolb, H.-J., Mittermüller, J., Clemm, C., et al. (1990) · Blood · doi:10.1182/blood.v76.12.2462.2462 · Cited by 1,521 · see citing works

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

WEIDEN, P. L., Flournoy, N., Thomas, E. D., Prentice, R. L., Fefer, A., Buckner, C. D., & Storb, R. F. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905103001902 · Cited by 1,512 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

B lymphocytes: how they develop and function

LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400 · see citing works

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,336 · see citing works

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Collins, R. H., Shpilberg, O., Drobyski, W. R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.433 · Cited by 1,261 · see citing works

A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254 · see citing works

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · see citing works

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · see citing works

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

Giralt, S. A., Estey, E. H., Albitar, M. X., van Besien, K., Rondón, G., Anderlini, P. N., O'Brien, S. M., Khouri, I. F., Gajewski, J., Mehra, R. C., et al. (1997) · Blood · doi:10.1182/blood.v89.12.4531 · Cited by 1,135 · see citing works

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Gardner, R., Finney, O. C., Annesley, C., Brakke, H., Summers, C. N., Leger, K. J., Bleakley, M., Brown, C., Mgebroff, S., Kelly‐Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,124 · see citing works

Antileukemic Effect of Chronic Graft-versus-Host Disease

Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R. F., Thomas, E. D., & The Seattle Marrow Transplant Team (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042507 · Cited by 1,081 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation

Papadopoulos, E. B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M. H., Castro-Malaspina, H. R., Childs, B. H., Gillio, A. P., Small, T. N., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301703 · Cited by 1,040 · see citing works

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,031 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,020 · see citing works

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works

Therapeutic T cell engineering

Sadelain, M., Rivière, I., & Riddell, S. R. (2017) · Nature · doi:10.1038/nature22395 · Cited by 880 · see citing works

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860 · see citing works

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844 · see citing works

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843 · see citing works

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G. A. N., Durrant, I. J., Luger, S. M., Marks, D. I., FRANKLIN, I. M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841 · see citing works

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833 · see citing works

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807 · see citing works

The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways

Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 806 · see citing works

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

Till, B. G., Jensen, M. C., Wang, J., Chen, E., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A. A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 721 · see citing works

CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA

COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717 · see citing works

CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes

Carter, R. H., & Fearon, D. T. (1992) · Science · doi:10.1126/science.1373518 · Cited by 683 · see citing works

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 677 · see citing works

Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice

Rickert, R. C., Rajewsky, K., & Roes, J. (1995) · Nature · doi:10.1038/376352a0 · Cited by 672 · see citing works

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669 · see citing works

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

Rosenberg, S. A., Lotze, M. T., Yang, J., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P. M., Leitman, S. F., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 638 · see citing works

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Sterner, R. M., Sakemura, R. L., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2018) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 632 · see citing works

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C.-H., Saso, K., Butler, M. O., Minden, M. D., & Hirano, N. (2018) · Nature Medicine · doi:10.1038/nm.4478 · Cited by 624 · see citing works

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Burstein, H. J., Krilov, L., Aragon‐Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., Groot, J. F. D., Devine, S. M., DuBois, S. G., El‐Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 601 · see citing works

Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli

Rosenberg, S. A., Grimm, E. A., McGrogan, M. P., DOYLE, M. V., Kawasaki, E. S., Koths, K. E., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595 · see citing works

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 589 · see citing works

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Choi, B. D., Yu, X., Castaño, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., Bailey, S. R., Boroughs, A. C., Frigault, M. J., Leick, M. B., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0192-1 · Cited by 575 · see citing works

The pharmacology of second-generation chimeric antigen receptors

van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 562 · see citing works

Abnormal B lymphocyte delevopment, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule

Engel, P., Zhou, L., Ord, D. C., Sato, S., Koller, B., & Tedder, T. F. (1995) · Immunity · doi:10.1016/1074-7613(95)90157-4 · Cited by 540 · see citing works

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537 · see citing works

Targeting tumours with genetically enhanced T lymphocytes

Sadelain, M., Rivière, I., & Brentjens, R. J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc971 · Cited by 533 · see citing works

CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells

Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., González, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 485 · see citing works

The promise and potential pitfalls of chimeric antigen receptors

Sadelain, M., Brentjens, R. J., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 469 · see citing works

Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

Brentjens, R. J., Santos, E. B., Nikhamin, Y., Yeh, R., Matsushita, M., Perle, K. L., Quintás‐Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463 · see citing works

Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow

Barnes, D. W. H., Loutit, J. F., & Neal, F. E. (1956) · BMJ · doi:10.1136/bmj.2.4993.626 · Cited by 461 · see citing works

CD22 blockade restores homeostatic microglial phagocytosis in ageing brains

Pluvinage, J. V., Haney, M. S., Smith, B. A. H., Sun, J., Iram, T., Bonanno, L., Li, L., Lee, D. P., Morgens, D. W., Yang, A. C., et al. (2019) · Nature · doi:10.1038/s41586-019-1088-4 · Cited by 459 · see citing works

CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors

Chmielewski, M. M., & Abken, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.063 · Cited by 432 · see citing works

Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides

Romeo, C., & Seed, B. (1991) · Cell · doi:10.1016/0092-8674(91)90327-u · Cited by 396 · see citing works

Retrovirus Packaging Cells

Miller, A. D. (1990) · Human Gene Therapy · doi:10.1089/hum.1990.1.1-5 · Cited by 388 · see citing works

Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells

Kahlon, K. S., Brown, C. E., Cooper, L. J. N., Raubitschek, A. A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 369 · see citing works

Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes

Krause, A., Guo, H.-F., Latouche, J., Tan, C., Cheung, N. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 368 · see citing works

Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML

Perna, F., Berman, S., Soni, R. K., Mansilla‐Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 345 · see citing works

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S. M., Bórquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316 · see citing works

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

Dudley, M. E., Gross, C. A., Langhan, M. M., García, M. R., Sherry, R. M., Yang, J. C.-H., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 313 · see citing works

T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins.

Letourneur, F., & Klausner, R. D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8905 · Cited by 308 · see citing works

Lymphokine-activated killer cells: A new approach to immunotherapy of cancer

Rosenberg, S. A. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/75.4.595 · Cited by 308 · see citing works

T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

Stephan, M. T., Ponomarev, V., Brentjens, R. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 300 · see citing works

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Mulé, J. J., Shu, S., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.1.646 · Cited by 295 · see citing works

Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284 · see citing works

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C.-H., Sherry, R. M., Feldman, S. A., McIntyre, L. S., Bot, A. I., Rossi, J. M., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 284 · see citing works

High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M., & Morgan, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7739 · Cited by 258 · see citing works

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Kerkar, S. P., Muranski, P. J., Kaiser, A., Boni, A., Sanchez-Perez, L. A., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254 · see citing works

Donor T Cells to Treat EBV-Associated Lymphoma

Heslop, H. E., Brenner, M. K., & Rooney, C. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311017 · Cited by 252 · see citing works

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02079 · Cited by 242 · see citing works

Pharmacologic control of CAR-T cell function using dasatinib

Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 240 · see citing works

Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen

Gong, M., Latouche, J., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 238 · see citing works

Peripheral blood lymphocytes as target cells of retroviral vector- mediated gene transfer

Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., Traversari, C., & Bordignon, C. (1994) · Blood · doi:10.1182/blood.v83.7.1988.1988 · Cited by 237 · see citing works

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor

Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210 · see citing works

Designing chimeric antigen receptors to effectively and safely target tumors

Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204 · see citing works

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 191 · see citing works

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells

Drent, E., Poels, R., Ruiter, R. W. J., van de Donk, N. W. C. J., Zweegman, S., Yuan, H., de Bruijn, J. D., Sadelain, M., Lokhorst, H. M., Groen, R. W. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2559 · Cited by 190 · see citing works

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 186 · see citing works

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 186 · see citing works

Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells

Brocker, T. (2000) · Blood · doi:10.1182/blood.v96.5.1999 · Cited by 173 · see citing works

Recombinant Retroviruses Pseudotyped With the Vesicular Stomatitis Virus G Glycoprotein Mediate Both Stable Gene Transfer and Pseudotransduction in Human Peripheral Blood Lymphocytes

Gallardo, H. F., Tan, C., Ory, D. S., & Sadelain, M. (1997) · Blood · doi:10.1182/blood.v90.3.952 · Cited by 170 · see citing works

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR

Willemsen, R. A., Weijtens, M. E. M., Ronteltap, C. P. M., Eshhar, Z., Gratama, J. W., Chames, P., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301253 · Cited by 170 · see citing works

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156 · see citing works

Cellular Basis of the Immunological Defects in Thymectomized Mice

Miller, J. F. A. P., Mitchell, G. F., & WEISS, N. S. (1967) · Nature · doi:10.1038/214992a0 · Cited by 155 · see citing works

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Heymach, J. V., Krilov, L., Alberg, A. J., Baxter, N. N., Chang, S. M., Corcoran, R. B., Dale, W., DeMichele, A. M., Diefenbach, C., Dreicer, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0446 · Cited by 139 · see citing works

Rational development of high-affinity T-cell receptor-like antibodies

Stewart-Jones, G., Wadle, A., Hombach, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901425106 · Cited by 129 · see citing works

Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL

Goff, S. L., Smith, F. O., Klapper, J. A., Sherry, R. M., Wunderlich, J. R., Steinberg, S. M., White, D., Rosenberg, S. A., Dudley, M. E., & Yang, J. C.-H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f05b91 · Cited by 123 · see citing works

Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment

Barber, A. E., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 101 · see citing works

The T-body approach: potential for cancer immunotherapy

Eshhar, Z., Bach, N., Fitzer‐Attas, C. J., et al. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00820666 · Cited by 98 · see citing works

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

Wang, X., & Rivière, I. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.81 · Cited by 96 · see citing works

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity

Maus, M. V., Plotkin, J., Jakka, G., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.23 · Cited by 96 · see citing works

Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect.

Higano, C. S., Brixey, M., Bryant, E. M., et al. (1990) · PubMed · Cited by 93 · see citing works

New simplified molecular design for functional T cell receptor

Brocker, T., Peter, A., Traunecker, A., et al. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230705 · Cited by 83 · see citing works

Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.

Altenschmidt, U., Kahl, R., Moritz, D. R., et al. (1996) · PubMed · Cited by 78 · see citing works

DURABLE COMPLETE REMISSION OF ACUTE NONLYMPHOCYTIC LEUKEMIA ASSOCIATED WITH DISCONTINUATION OF IMMUNOSUPPRESSION FOLLOWING RELAPSE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION

&NA; (1990) · Transplantation · doi:10.1097/00007890-199007000-00038 · Cited by 77 · see citing works

CAR T-Cell Therapy in Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., & Go, W. Y. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1800913 · Cited by 58 · see citing works

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel

Schuster, S. J., Bishop, M. R., Tam, C. S. L., Borchmann, P., Jaeger, U., Waller, E. K., Holte, H., McGuirk, J. P., Jaglowski, S. M., Tobinai, K., et al. (2018) · Blood · doi:10.1182/blood-2018-99-115252 · Cited by 45 · see citing works

Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer

Bendle, G. M., Linnemann, C., Bies, L., Song, J., & Schumacher, T. N. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301270 · Cited by 43 · see citing works

About human tumor antigens to be used in immunotherapy

Lucas, S., & Coulie, P. G. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.02.001 · Cited by 40 · see citing works

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).

Vidula, N., Juric, D., Niemierko, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1020 · Cited by 40 · see citing works

Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells

Abken, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.115 · Cited by 39 · see citing works

The making and function of CAR cells

Zabel, M., Tauber, P. A., & Pickl, W. F. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.06.002 · Cited by 30 · see citing works

Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Walton, M., Sharif, S., Simmonds, M. C., et al. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00799-0 · Cited by 26 · see citing works

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687 · see citing works

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies

Yulin, X., Yongxian, H., Xiangjun, C., et al. (2020) · Guoji shuxue ji xueyexue zazhi · doi:10.3760/cma.j.issn.1673-419x.2020.01.001

The present situation and prospect of CAR-T cellular immunotherapy

Wang, B., Li, C., & Yang, Y. (2020) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2020.01.018

CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements

Li, C., Liu, Z., & Zhou, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1110 · Cited by 3 · see citing works

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 64 · see citing works

Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence

Sun, W., Jiang, Z., Jiang, W. G., & Yang, R. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100638 · Cited by 17 · see citing works